

SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): January 30, 2007

TECHNE CORPORATION  
(Exact Name of Registrant as Specified in Charter)

Minnesota	0-17272	41-1427402
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	I.R.S. Employer Identification No.)

614 Mckinley Place NE	
Minneapolis, MN	55413
(Address of Principal Executive Offices)	(Zip Code)

Registrant's telephone number, including area code: (612) 379-8854

Not Applicable  
(Former Name or Former Address, if changed since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

- // Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- // Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- // Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- // Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02 Results of Operations and Financial Condition

A copy of the press release issued by Techne Corporation on January 30, 2007, describing the results of operations for the quarter and six months ended December 31, 2006 and its financial condition as of December 31, 2006, is attached hereto as Exhibit 99.1.

Segment information for Techne Corporation for the quarter and six months ended December 31, 2006 which has been included on Techne Corporation's website ([www.techne-corp.com](http://www.techne-corp.com)), is attached hereto as Exhibit 99.2.

The information in this Form 8-K and the Exhibits attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

99.1 Press Release dated January 30, 2007.

99.2 Segment information for the quarter and six months ended  
December 31, 2006.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: January 30, 2007                      TECHNE CORPORATION

By: /s/ Thomas E. Oland

-----  
Name: Thomas E. Oland  
Title: President and Chief  
Executive Officer

EXHIBIT INDEX

Exhibit No. Description

- 
- 99.1 Press release of Techne Corporation dated January 30, 2007.
  - 99.2 Segment information for Techne Corporation for the quarter and six months ended December 31, 2006.

TECHNE CORPORATION RELEASES UNAUDITED SECOND QUARTER  
RESULTS FOR FISCAL YEAR 2007

Minneapolis/January 30, 2007--Techne Corporation's (NASDAQ: TECH) consolidated net earnings for the quarter ended December 31, 2006 increased 13.0% to \$18.7 million or \$0.47 per diluted share compared to \$16.5 million and \$0.42 per diluted share for the quarter ended December 31, 2005. For the six months ended December 31, 2006, Techne's consolidated net earnings increased 14.3% to \$38.3 million or \$0.97 per diluted share compared with \$33.5 million or \$0.84 per diluted share for the six months ended December 31, 2005. The improvement in results was mainly due to increased consolidated net sales and improved gross margin percentages.

Consolidated net sales for the quarter and six months ended December 31, 2006 were \$52.5 million and \$104.9 million, respectively. This was an increase of 9.3% and 9.5% from the quarter and six months ended December 31, 2005.

Biotechnology net sales, which includes sales by R&D Systems' Biotechnology Division, Fortron and BiosPacific, for the quarter and six months ended December 31, 2006 were \$33.4 million and \$69.3 million, increases of 7.3% and 9.3%, respectively, from the same prior-year periods. Net sales for the Biotechnology Division increased 11.1% and 10.9% for the quarter and six months ended December 31, 2006, respectively, mainly as a result of increased volume from the same prior-year periods. Approximately \$500,000 and \$1.2 million of the increase in Biotechnology Division net sales for the quarter and six months ended December 31, 2006, respectively, was the result of price increases. BiosPacific net sales increased for the quarter ended September 30, 2006 from the first quarter of the prior year, but decreased from the prior year for the quarter ended December 31, 2006 due to the timing of large shipments to diagnostic customers.

R&D Europe's net sales for the quarter and six months ended December 31, 2006 were \$15.3 million and \$28.2 million, increases of 16.4% and 12.8%, respectively, from the same prior-year periods. In British pound sterling, R&D Europe's net sales increased 4.3% and 3.5% for the quarter and six months ended December 31, 2006. Hematology net sales for the quarter and six months ended December 31, 2006 were \$3.8 million and \$7.3 million, increases of 1.2% and 0.2%, respectively, compared to the quarter and six months ended December 31, 2005.

Consolidated gross margins were 79.6% and 79.1% for the quarter and six months ended December 31, 2006, respectively, compared to 77.7% and 77.2% for the quarter and six months ended December 31, 2005. Biotechnology gross margins increased to 80.8% and 80.2% for the quarter and six months ended December 31, 2006 from 78.4% and 77.9% for the same prior-year periods mainly as a result of changes in product mix. Biotechnology gross margins were also affected by the sale of inventory acquired from Fortron and BiosPacific in fiscal 2006, which was valued at fair market under purchase accounting. Included in cost of sales for the quarter and six months ended December 31, 2006 were \$64,000 and \$355,000, respectively, related to the sale of acquired inventory compared to \$281,000 and \$856,000, respectively, for the same prior year periods.

Consolidated net earnings and diluted earnings per share for the quarter and six months ended December 31, 2006 were favorably impacted by the change in exchange rates from the prior year used to convert R&D Europe results from British pound sterling to U.S. dollars. The change in exchange rates from the prior year increased consolidated net earnings approximately \$466,000 and \$672,000 for the quarter and six months ended December 31, 2006, respectively.

In October 2006, the Company repaid its mortgage debt. The total payment of \$13.8 million included the mortgage principal balance, accrued interest and a 5% prepayment penalty of \$651,000. The prepayment penalty and \$78,000 of unamortized loan origination fees were included in interest expense for the quarter ended December 31, 2006.

**Forward Looking Statements:**

This earnings release may contain forward-looking statements within the meaning of the Private Litigation Reform Act. These statements involve risks and uncertainties that may affect the actual results of operations. The following important factors, among others, have affected and, in the future, could affect the Company's actual results: the introduction and acceptance of

new biotechnology and hematology products, the levels and particular directions of research by the Company's customers, the impact of the growing number of producers of biotechnology research products and related price competition, the retention of hematology OEM and proficiency survey business, the impact of currency exchange rate fluctuations, and the costs and results of research and product development efforts of the Company and of companies in which the Company has invested or with which it has formed strategic relationships. For additional information concerning such factors, see the Company's annual report on Form 10-K and quarterly reports on Form 10-Q as filed with the Securities and Exchange Commission. We undertake no obligation to update or revise any forward-looking statements we make in this release due to new information or future events. Investors are cautioned not to place undue emphasis on these statements.

\* \* \* \* \*

Techne Corporation has two operating subsidiaries: Research and Diagnostic Systems, Inc. (R&D Systems) of Minneapolis, Minnesota and R&D Systems Europe, Ltd. (R&D Europe) of Abingdon, England. R&D Systems is a specialty manufacturer of biological products. R&D Systems has two subsidiaries, Fortron Bio Science, Inc. (Fortron), located in Minneapolis, and BiosPacific, Inc. (BiosPacific), located in Emeryville, California. Fortron develops and manufactures antibodies and BiosPacific is a worldwide supplier of biologics to manufacturers of in vitro diagnostic systems and immunodiagnostic kits. R&D Europe is a distributor of biotechnology products.

Contact: Greg Melsen, Chief Financial Officer  
 Kathy Backes, Controller  
 (612) 379-8854

TECHNE CORPORATION  
 CONSOLIDATED STATEMENTS OF EARNINGS  
 (In thousands, except per share data)  
 (Unaudited)

	QUARTER ENDED		SIX MONTHS ENDED	
	12/31/06	12/31/05	12/31/06	12/31/05
Net sales	\$52,509	\$48,029	\$104,860	\$95,738
Cost of sales	10,714	10,695	21,951	21,791
Gross margin	41,795	37,334	82,909	73,947
Operating expenses:				
Selling, general and administrative	8,830	7,980	15,897	14,434
Research and development	5,044	4,574	9,899	9,291
Amortization of intangible assets	404	492	807	984
Total operating expenses	14,278	13,046	26,603	24,709
Operating income	27,517	24,288	56,306	49,238
Other expense (income):				
Interest expense	815	238	1,083	461
Interest income	(1,956)	(1,130)	(3,632)	(2,104)
Other non-operating expense (income), net	428	281	913	492
Total other expense (income)	(713)	(611)	(1,636)	(1,151)
Earnings before income taxes	28,230	24,899	57,942	50,389
Income taxes	9,567	8,385	19,648	16,874
Net earnings	\$18,663	\$16,514	\$38,294	\$33,515

Earnings per share:				
Basic	\$ 0.47	\$ 0.42	\$ 0.97	\$ 0.86
Diluted	\$ 0.47	\$ 0.42	\$ 0.97	\$ 0.84
Weighted average common shares outstanding:				
Basic	39,387	38,877	39,383	38,815

Diluted 39,511 39,761 39,483 39,730

TECHNE CORPORATION  
CONSOLIDATED BALANCE SHEETS  
(In thousands)  
(Unaudited)

	12/31/06	6/30/06
ASSETS		
Cash and equivalents	\$102,558	\$ 89,634
Short-term available-for-sale investments	23,751	19,212
Trade accounts receivable	22,923	23,769
Other receivables	1,355	1,309
Inventory	9,210	9,024
Other current assets	7,426	6,874
Current assets	167,223	149,822
Available-for-sale investments	80,205	77,660
Property and equipment, net	90,045	88,772
Goodwill and intangible assets, net	31,215	32,021
Other non-current assets	28,954	22,237
Total assets	\$397,642	\$370,512
LIABILITIES		
Current liabilities	\$ 12,160	\$ 17,966
Long-term debt	--	12,198
Stockholders' equity	385,482	340,348
Total liabilities and equity	\$397,642	\$370,512

SEGMENT INFORMATION  
TECHNE CORPORATION AND SUBSIDIARIES  
(in thousands of \$'s, except per share data)

	Increase (Decrease)						
	Fiscal 2007			From Fiscal 2006			
	First Quarter	Second Quarter	Percent YTD	First Quarter	Second Quarter	Percent YTD	YTD
Sales	52,351	52,509	104,860	100%	4,642	4,480	9,122
Cost of sales	11,237	10,714	21,951	21%	141	19	160
Gross margin	41,114	41,795	82,909	79%	4,501	4,461	8,962
Gross margin percentage	78.5%	79.6%	79.1%				
SG&A expense	7,067	8,830	15,897	15%	613	850	1,463
R&D expense	4,855	5,044	9,899	9%	138	470	608
Amortization expense	403	404	807	1%	(89)	(88)	(177)
Interest expense	268	815	1,083	1%	45	577	622
Interest income	(1,676)	(1,956)	(3,632)	(3%)	(702)	(826)	(1,528)
Other non-operating ex., net	485	428	913	1%	274	147	421
	11,402	13,565	24,967	24%	279	1,130	1,409
Earnings before income taxes	29,712	28,230	57,942	55%	4,222	3,331	7,553
Income taxes	10,081	9,567	19,648	18%	1,592	1,182	2,774
	19,631	18,663	38,294	37%	2,630	2,149	4,779
Diluted earnings per share	0.50	0.47	0.97				
Weighted average diluted shares outstanding	39,469	39,511	39,483				

BIOTECHNOLOGY (1)  
(in thousands of \$'s)

	Increase (Decrease)						
	Fiscal 2007			From Fiscal 2006			
	First Quarter	Second Quarter	Percent YTD	First Quarter	Second Quarter	Percent YTD	YTD
Sales	41,621	40,073	81,694	100%	4,022	2,376	6,398
Intersegment sales	(5,699)	(6,647)	(12,346)		(400)	(92)	(492)
	35,922	33,426	69,348		3,622	2,284	5,906
Cost of sales	8,482	7,683	16,165	20%	12	(464)	(452)
Intersegment sales	(5,524)	(6,435)	(11,959)		(201)	(295)	(496)
	2,958	1,248	4,206		(189)	(759)	(948)
Gross margin	32,964	32,178	65,142	80%	3,811	3,043	6,854
Gross margin percentage	79.6%	80.8%	80.2%				
SG&A expense	4,013	4,664	8,677	11%	374	470	844
R&D expense	4,675	4,854	9,529	12%	143	450	593
Amortization expense	403	404	807	1%	(89)	(88)	(177)
Interest, net	(595)	(722)	(1,317)	(2%)	(327)	(349)	(676)

	8,496	9,200	17,696	22%	101	483	584
Pretax result	24,468	22,978	47,446	58%	3,710	2,560	6,270

(1) Includes R&D Systems' Biotechnology Division, Fortron Bio Science, Inc., and BiosPacific, Inc.

R&D SYSTEMS EUROPE  
(in thousands of British pounds)

	Fiscal 2007		Increase (Decrease) From Fiscal 2006		Percent Of Sales		YTD
	First Quarter	Second Quarter	First Quarter	Second Quarter	First Quarter	Second Quarter	
Sales	6,870	7,851	14,721	100%	180	322	502
Cost of sales	3,285	3,766	7,051	48%	(7)	1	(6)
Gross margin	3,585	4,085	7,670	52%	187	321	508
Gross margin percentage	52.2%	52.0%	52.1%				
SG&A expense	1,074	1,236	2,310	16%	70	51	121
Interest income	(410)	(480)	(890)	(6%)	(84)	(151)	(235)
Exchange loss/(gain)	78	(64)	14	--	63	(90)	(27)
	742	692	1,434	10%	49	(190)	(141)
Pretax result	2,843	3,393	6,236	42%	138	511	649

R&D SYSTEMS EUROPE  
(in thousands of \$'s)

	Fiscal 2007		Increase (Decrease) From Fiscal 2006		Percent Of Sales		YTD
	First Quarter	Second Quarter	First Quarter	Second Quarter	First Quarter	Second Quarter	
Sales	12,927	15,257	28,184	100%	1,052	2,151	3,203
Cost of sales	6,181	7,319	13,500	48%	337	765	1,102
Gross margin	6,746	7,938	14,684	52%	715	1,386	2,101
Gross margin percentage	52.2%	52.0%	52.1%				
SG&A expense	2,020	2,405	4,425	16%	238	346	584
Interest income	(771)	(933)	(1,704)	(6%)	(192)	(361)	(553)
Exchange loss	147	(126)	21	--	119	(172)	(53)
	1,396	1,346	2,742	10%	165	(187)	(22)
Pretax result	5,350	6,592	11,942	42%	550	1,573	2,123

HEMATOLOGY  
(in thousands of \$'s)

	Fiscal 2007		Increase (Decrease) From Fiscal 2006	
	First Quarter	Second Quarter	First Quarter	Second Quarter

	Quarter	Quarter	YTD	Of Sales	Quarter	Quarter	YTD
Sales	3,502	3,826	7,328	100%	(32)	45	13
Cost of sales	2,098	2,147	4,245	58%	(7)	13	6
Gross margin	1,404	1,679	3,083	42%	(25)	32	7
Gross margin percentage	40.1%	43.9%	42.1%				
SG&A expense	398	439	837	11%	14	15	29
R&D expense	180	190	370	5%	(5)	20	15
Interest, net	(81)	(95)	(176)	(2%)	(44)	(45)	(89)
	497	534	1,031	14%	(35)	(10)	(45)
Pretax result	907	1,145	2,052	28%	10	42	52

CORPORATE AND OTHER (2)  
(in thousands of \$'s)

	Increase (Decrease)					
	Fiscal 2007		From Fiscal 2006			
	First Quarter	Second Quarter	YTD	First Quarter	Second Quarter	YTD
Interest income	229	206	435	139	71	210
Rental income	299	241	540	(43)	(96)	(139)
	528	447	975	96	(25)	71
SG&A expense	636	1,322	1,958	(13)	19	6
Interest expense	268	815	1,083	45	577	622
Other-Building expenses	510	549	1,059	67	59	126
Other-Hemerus losses	127	123	250	45	41	86
Other-Nephromics losses	--	123	123	--	123	123
	1,541	2,932	4,473	144	819	963
Pretax result	(1,013)	(2,485)	(3,498)	(48)	(844)	(892)

(2) Unallocated corporate expenses and Techne's share of losses by Hemerus Medical, LLC and Nephromics, LLC.